OLIGONUCLEOTIDES WITH ANTI-MDR-1 GENE ACTIVITY
Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to at least a portion of the multi-drug resistant-1 gene, or transcripts thereof, which portion encodes a nucleoside binding site. Also disclosed is a pharmaceutical formulation containing such oligonucleotides, and...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SMYTH, ADRIENNE, P |
| description | Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to at least a portion of the multi-drug resistant-1 gene, or transcripts thereof, which portion encodes a nucleoside binding site. Also disclosed is a pharmaceutical formulation containing such oligonucleotides, and methods of treating multidrug resistant cancer cells, of preventing the expression of P170 in a cell, and of preventing the induction of multidrug resistance in a cancer cell.
L'invention concerne un oligonucléotide synthétique comprenant une séquence nucléotidique complémentaire d'au moins une partie du gène 1 résistant à des médicaments multiples, ou des produits de transcription de ce dernier, ladite partie codant un site de liaison nucléosidique. Elle porte également sur une formule pharmaceutique contenant lesdits oligonucléotides et sur des méthodes de traitement des cellules cancéreuses résistant à de multiples médicaments, de prévention de l'expression de P170 dans une cellule, et de prévention de l'induction de la résistance à des médicaments multiples dans une cellule cancéreuse. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO9602556A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO9602556A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO9602556A23</originalsourceid><addsrcrecordid>eNrjZNDz9_F09_cLdfZx9Q_xdHENVgj3DPFQcPQL8dT1dQnSNVRwd_VzVXB0DvEM8wyJ5GFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8eH-lmYGRqamZo5GxkQoAQCgyyV-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>OLIGONUCLEOTIDES WITH ANTI-MDR-1 GENE ACTIVITY</title><source>esp@cenet</source><creator>SMYTH, ADRIENNE, P</creator><creatorcontrib>SMYTH, ADRIENNE, P</creatorcontrib><description>Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to at least a portion of the multi-drug resistant-1 gene, or transcripts thereof, which portion encodes a nucleoside binding site. Also disclosed is a pharmaceutical formulation containing such oligonucleotides, and methods of treating multidrug resistant cancer cells, of preventing the expression of P170 in a cell, and of preventing the induction of multidrug resistance in a cancer cell.
L'invention concerne un oligonucléotide synthétique comprenant une séquence nucléotidique complémentaire d'au moins une partie du gène 1 résistant à des médicaments multiples, ou des produits de transcription de ce dernier, ladite partie codant un site de liaison nucléosidique. Elle porte également sur une formule pharmaceutique contenant lesdits oligonucléotides et sur des méthodes de traitement des cellules cancéreuses résistant à de multiples médicaments, de prévention de l'expression de P170 dans une cellule, et de prévention de l'induction de la résistance à des médicaments multiples dans une cellule cancéreuse.</description><edition>6</edition><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; DERIVATIVES THEREOF ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; SUGARS ; VINEGAR ; WINE</subject><creationdate>1996</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19960201&DB=EPODOC&CC=WO&NR=9602556A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19960201&DB=EPODOC&CC=WO&NR=9602556A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SMYTH, ADRIENNE, P</creatorcontrib><title>OLIGONUCLEOTIDES WITH ANTI-MDR-1 GENE ACTIVITY</title><description>Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to at least a portion of the multi-drug resistant-1 gene, or transcripts thereof, which portion encodes a nucleoside binding site. Also disclosed is a pharmaceutical formulation containing such oligonucleotides, and methods of treating multidrug resistant cancer cells, of preventing the expression of P170 in a cell, and of preventing the induction of multidrug resistance in a cancer cell.
L'invention concerne un oligonucléotide synthétique comprenant une séquence nucléotidique complémentaire d'au moins une partie du gène 1 résistant à des médicaments multiples, ou des produits de transcription de ce dernier, ladite partie codant un site de liaison nucléosidique. Elle porte également sur une formule pharmaceutique contenant lesdits oligonucléotides et sur des méthodes de traitement des cellules cancéreuses résistant à de multiples médicaments, de prévention de l'expression de P170 dans une cellule, et de prévention de l'induction de la résistance à des médicaments multiples dans une cellule cancéreuse.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>DERIVATIVES THEREOF</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>SUGARS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1996</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDz9_F09_cLdfZx9Q_xdHENVgj3DPFQcPQL8dT1dQnSNVRwd_VzVXB0DvEM8wyJ5GFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8eH-lmYGRqamZo5GxkQoAQCgyyV-</recordid><startdate>19960201</startdate><enddate>19960201</enddate><creator>SMYTH, ADRIENNE, P</creator><scope>EVB</scope></search><sort><creationdate>19960201</creationdate><title>OLIGONUCLEOTIDES WITH ANTI-MDR-1 GENE ACTIVITY</title><author>SMYTH, ADRIENNE, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO9602556A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>1996</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>DERIVATIVES THEREOF</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>SUGARS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>SMYTH, ADRIENNE, P</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SMYTH, ADRIENNE, P</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>OLIGONUCLEOTIDES WITH ANTI-MDR-1 GENE ACTIVITY</title><date>1996-02-01</date><risdate>1996</risdate><abstract>Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to at least a portion of the multi-drug resistant-1 gene, or transcripts thereof, which portion encodes a nucleoside binding site. Also disclosed is a pharmaceutical formulation containing such oligonucleotides, and methods of treating multidrug resistant cancer cells, of preventing the expression of P170 in a cell, and of preventing the induction of multidrug resistance in a cancer cell.
L'invention concerne un oligonucléotide synthétique comprenant une séquence nucléotidique complémentaire d'au moins une partie du gène 1 résistant à des médicaments multiples, ou des produits de transcription de ce dernier, ladite partie codant un site de liaison nucléosidique. Elle porte également sur une formule pharmaceutique contenant lesdits oligonucléotides et sur des méthodes de traitement des cellules cancéreuses résistant à de multiples médicaments, de prévention de l'expression de P170 dans une cellule, et de prévention de l'induction de la résistance à des médicaments multiples dans une cellule cancéreuse.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO9602556A2 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA DERIVATIVES THEREOF ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS SUGARS VINEGAR WINE |
| title | OLIGONUCLEOTIDES WITH ANTI-MDR-1 GENE ACTIVITY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A56%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SMYTH,%20ADRIENNE,%20P&rft.date=1996-02-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO9602556A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |